Disruption of p53 by the viral oncoprotein HPV16-E6 does not deregulate chromosomal homologous recombination in a transcriptional interference-free assay system

Cell Cycle

Volumn 4, Issue 6, 2005, Pages 831-837

  Lemelin, Jean François ^a   Abaji, Christine ^a   Cousineau, Isabelle ^a   Belmaaza, Abdellah ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Homologous recombination; p53; Promoter suppression; RAD51; Transcriptional interference

Indexed keywords

PROTEIN P53; REPETITIVE DNA;

ARTICLE; CELL FREE SYSTEM; CHROMATIN STRUCTURE; CONTROLLED STUDY; GENE DISRUPTION; GENE REPRESSION; GENETIC RECOMBINATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN FUNCTION; RECEPTOR GENE; REPORTER GENE; TRANSCRIPTION INITIATION; VIRUS STRAIN;

EID: 25144477469     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.6.1725     Document Type: Article

References (73)

1. Carrington M, Cullen M. Justified, chauvinism: Advances in defining meiotic recombination through sperm typing. Trends Genet 2004; 20:196-205.
2. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat Res 2002; 509:49-78.
3. Kolomietz E, Meyn MS, Pandita A, Squire JA. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 2002; 35:97-112.
4. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003; 4:435-45.
5. Bi W, Park SS, Shaw CJ, Withers MA, Patel PI, Lupski JR. Reciprocal crossovers and a positional preference for strand exchange in recombination events resulting in deletion or duplication of chromosome 17p11.2. Am J Hum Genet 2003; 73:1302-15.
6. Tayebi N, Stubblefield BK, Park JK, Orvisky E, Walker JM, LaMarca ME, Sidransky E. Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: Implications for complexity in Gaucher disease. Am J Hum Genet 2003; 72:519-34.
7. Prado F, Cortes-Ledesma F, Huertas P, Aguilera A. Mitotic recombination in Saccharomyces cerevisiae. Curr Genet 2003; 42:185-98.
8. Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich S, Dietrich R, Gruhn B, Schindler D, Hoehn H. Reverse mosaicism in Fanconi anemia: Natural gene therapy via molecular self-correction. Cytogenet Genome Res 2002; 98:126-35.
9. Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, Owaribe K, Pulkkinen L, Uitto J. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 1997; 88:543-51.
10. Amor M, Parker KL, Globerman H, New MI, White PC. Mutation in the CYP21B gene (Ile-172 - Asn) causes steroid 21- hydroxylase deficiency. Proc Natl Acad Sci USA 1988; 85:16004.
11. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 2003; 33:97-101.
12. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305:779-84.
13. Ezquieta B, Cueva E, Oyarzabal M, Oliver A, Varela JM, Jariego C. Gene conversion (655G splicing mutation) and the founder effect (Gln318Stop) contribute to the most frequent severe point mutations in congenital adrenal hyperplasia (21-hydroxylase deficiency) in the Spanish population. Clin Genet 2002; 62:181-8.
14. Hauptschein RS, Gaidano G, Rao PH, Scotto L, Edwards YH, Chaganti RS, Dalla-Favera R. An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line. DNA Res 2000; 7:261-72.
15. Mazzei R, Gambardella A, Conforti FL, Magariello A, Patitucci A, Gabriele AL, Sprovieri T, Labate A, Valentino P, Bono F, et al. Gene conversion events in adult-onset spinal muscular atrophy. Acta Neurol Scand 2004; 109:151-4.
16. Bollag RJ, Waldman AS, Liskay RM. Homologous recombination in mammalian cells. Annu Rev Genet 1989; 23:199-225.
17. Bertrand P, Saintigny Y, Lopez BS. p53's double life: Transactivation-independent repression of homologous recombination. Trends Genet 2004; 20:235-43.
18. Meyn MS. High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia. Science 1993; 260:1327-30.
19. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
20. Janz C, Susse S, Wiesmuller L. p53 and recombination intermediates: Role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation. Oncogene 2002; 21:2130-40.
21. Sturzbecher HW, Donzelmann B, Henning W, Knippschild U, Buchhop S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 1996; 15:1992-2002.
22. Susse S, Janz C, Janus F, Deppert W, Wiesmuller L. Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53. Oncogene 2000; 19:4500-12.
23. Gersten KM, Kemp CJ. Normal meiotic recombination in p53-deficient mice. Nat Genet 1997; 17:378-9.
24. Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B, Lengauer C. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002; 62:1129-33.
25. Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, Garfield SH, Valerie K, Shay JW, Ellis NA, Wasylyk B, Harris CC. BLM helicase-dependent transport of p53 to sites of stalled. DNA replication forks modulates homologous recombination. EMBO J 2003; 22:1210-22.
26. Hirano T. Cell biology: Holding sisters for repair. Nature 2005; 433:467-8.
27. Khanna KK, Jackson SP. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 2001; 27:247-54.
28. van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001; 2:196-206.
29. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171-82.
30. Dominguez-Bendala J, Priddle H, Clarke A, McWhir J. Elevated expression of exogenous Rad51 leads to identical increases in gene-targeting frequency in murine embryonic stem (ES) cells with both functional and dysfunctional p53 genes. Exp Cell Res 2003; 286:298-307.
31. Villemure JF, Belmaaza A. Effects of sequence divergence on the efficiency of extrachromosomal recombination in mismatch repair proficient and deficient mammalian cell lines. Somat Cell Mol Genet 1999; 25:79-90.
32. Willers H, McCarthy EE, Hubbe P, Dahm-Daphi J, Powell SN. Homologous recombination in extrachromosomal plasmid substrates is not suppressed by p53. Carcinogenesis 2001; 22:1757-63.
33. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10:404-8.
34. Eszterhas SK, Bouhassira EE, Martin DI, Fiering S. Transcriptional interference by independently regulated genes occurs in any relative arrangement of the genes and is influenced by chromosomal integration position. Mol Cell Biol 2002; 22:469-79.
35. Villemure JF, Savard N, Belmaaza A. Promoter suppression in cultured mammalian cells can be blocked by the chicken beta-globin chromatin insulator 5′HS4 and matrix/scaffold attachment regions. J Mol Biol 2001; 312:963-74.
36. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 1998; 95:13869-74.
37. Abaji C, Cousineau I, Belmaaza A. BRCA2 regulates homologous recombination in response to DNA damage: Implications for genome stability and carcinogenesis. Cancer Res 2005; In press.
38. Mekeel KL, Tang W, Kachnic LA, Luo CM, DeFrank JS, Powell SN. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997; 14:1847-57.
39. Capizzi RL, Jameson JW. A table for the estimation of the spontaneous mutation rate of cells in culture. Mutat Res 1973; 17:147-8.
40. Villemure JF, Abaji C, Cousineau I, Belmaaza A. MSH2-deficient human cells exhibit a defect in the accurate termination of homology-directed repair of DNA double-strand breaks. Cancer Res 2003; 63:3334-9.
41. Hasegawa K, Nakatsuji N. Insulators prevent transcriptional interference between two promoters in a double gene construct for transgenesis. FEBS Lett 2002; 520:47-52.
42. Gupta M, Fan S, Zkan Q, Kohn KW, O'Connor PM, Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res 1997; 3:1653-60.
43. Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J 2000; 19:3398-407.
44. Taghian DG, Nickoloff JA. Chromosomal double-strand breaks induce gene conversion at high frequency in mammalian cells. Mol Cell Biol 1997; 17:6386-93.
45. Das GC, Shivakumar CV, Todd SD. Cell-specific modulation of the papovavirus promoters by tumor-suppressor protein p53 in the absence of large T-antigen. Oncogene 1995; 10:449-55.
46. Deb D, Lanyi A, Scian M, Keiger J, Brown DR, Le Roith D, Deb SP, Deb S. Differential modulation of cellular and viral promoters by p73 and p53. Int J Oncol 2001; 18:401-9.
47. Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K, Pomerantz RJ. The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol 1994; 68:4302-13.
48. Kang YH, Kang MJ, Paik SG, Park SN, Yoon DY. Repression of HPV E6-activated RSV promoter activity by anti-cancer agents. Antiviral Res 2003; 58:65-71.
49. Mori N, Kashanchi F, Prager D. Repression of transcription from the human T-cell leukemia virus type I long terminal repeat and cellular gene promoters by wild-type p53. Blood 1997; 90:4924-32.
50. Subler MA, Martin DW, Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J Virol 1992; 66:4757-62.
51. Subler MA, Martin DW, Deb S. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol 1994a; 68:103-10.
52. Subler MA, Martin DW, Deb S. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 1994b; 9:1351-9.
53. Takada S, Kaneniwa N, Tsuchida N, Koike K. Hepatitis B virus X gene expression is activated by X protein but repressed by p53 tumor suppressor gene product in the transient expression system. Virology 1996; 216:80-9.
54. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13:2490-501.
55. Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001; 58:721-7.
56. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev 1999; 9:158-63.
57. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, Wilson C, Lander E, Jaenisch R. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet 2001; 27:31-39.
58. Nasr AP, Nutini M, Palombo B, Guerra E, Alberti S. Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene. Oncogene 2003; 22:1668-77.
59. Bird AW, Yu DY, Pray-Grant MG, Qiu Q, Harmon KE, Megee PC, Grant PA, Smith MM, Christman MF. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 2002; 419:411-5.
60. Maloisel L, Rossignol JL. Suppression of crossing-over by DNA methylation in Ascobolus. Genes Dev 1998; 12:1381-9.
61. Smith ML, Bortnick RA, Sheikh MS, Fornace Jr AJ. Chromatin relaxation by overexpression of mutant p53, HPV16-E6, or cyclin G transgenes. Exp Cell Res 1998; 242:235-243.
62. Akyuz N, Boehden GS, Susse S, Rimek A, Preuss U, Scheidtmann KH, Wiesmuller L. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 2002; 22:6306-17.
63. 1 checkpoint. Oncogene 1999; 18:3553-63.
64. 1/S cell cycle checkpoint control. Oncogene 2000; 19:632-9.
65. Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res 1986; 14:9381-96.
66. Okorokov AL, Rubbi CP, Metcalfe S, Milner J. The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 2002; 21:356-67.
67. Kim E, Deppert W. The complex interactions of p53 with target DNA: We learn as we go. Biochem Cell Biol 2003; 81:141-50.
68. Cook JL, Zhang Z, Alam J, Re RN. Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies. Oncogene 1999; 18:2373-9.
69. Rubbi CP, Milner J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J 2003; 22:975-86.
70. Kumari A, Schultz N, Helleday T. p53 protects from replication-associated DNA double-strand breaks in mammalian cells. Oncogene 2004; 23:2324-9.
71. Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, Adams PD. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell 2003; 11:341-51.
72. Lomonosov M, Anand S, Sangrithi M, Davies R, Venkitaraman AR. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev 2003; 17:3017-22.
73. Whitelaw E, Martin DI. Retro transposons as epigenetic mediators of phenotypic variation in mammals. Nat Genet 2001; 27:361-5.